Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Phase III comparison of two CPT-11 dosing regimens (weekly x 4 every-6-weeks vs every-3-weeks) in second-line metastatic colorectal cancer (MCRC) therapy

Phase III comparison of two CPT-11 dosing regimens (weekly x 4 every-6-weeks vs every-3-weeks) in second-line metastatic colorectal cancer (MCRC) therapy. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings. 2002.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.